Inside Merck’s High-Stakes Patent Cliff Defense As Subcutaneous Keytruda Gains Traction

Inside Merck’s High-Stakes Patent Cliff Defense As Subcutaneous Keytruda Gains Traction

Merck beat quarterly earnings expectations and raised its full-year profit outlook largely because its newly launched subcutaneous formulation of Keytruda is converting patients faster than Wall Street anticipated. This early commercial momentum provides critical validation for the company’s primary defense against the impending 2028 patent expiration of its flagship intravenous cancer therapy. While headline numbers show strong immediate revenue growth and operational discipline, the underlying story is a high-wire act of lifecycle management, payer negotiations, and fierce competition in the oncology market.

Wall Street loves a clean earnings beat. When a pharmaceutical giant raises its guidance, institutional investors tend to reward the stock first and ask structural questions later. Yet anyone who has watched the biopharmaceutical industry over the past three decades knows that single-quarter outperformance often masks existential long-term anxieties. Merck is currently generating massive cash flows from a single biological asset, pembrolizumab, sold under the brand name Keytruda. It is the best-selling prescription medicine on the planet, pulling in tens of billions of dollars annually and accounting for roughly half of the company's total top-line revenue.

That kind of concentration is both a blessing and a ticking time bomb.

In the pharmaceutical business, exclusivity is temporary. By 2028, key composition-of-matter patents protecting intravenous Keytruda in the United States will expire, opening the floodgates to biosimilar competitors. When biosimilars hit the market, prices do not gently erode; they collapse. Merck’s entire corporate strategy over the last five years has been engineered around softening that blow, and the rapid uptake of subcutaneous Keytruda is the centerpiece of that defensive wall.

The Mechanics of the Subcutaneous Shift

To understand why a change in how a drug is injected matters so much to a company's valuation, you have to look at the intersection of clinical pharmacology, hospital economics, and patent law.

Traditional Keytruda is administered via an intravenous infusion. A cancer patient has to travel to an infusion center, sit in a chair for thirty minutes to an hour while a nurse accesses a vein or a port, and wait for the monoclonal antibody to drip into their bloodstream. It is time-consuming for patients and resource-intensive for healthcare systems.

The new formulation changes the delivery method entirely. By combining pembrolizumab with a recombinant human hyaluronidase enzyme—technology licensed through a strategic partnership with Alteogen—Merck created a version that can be injected directly under the skin in a matter of minutes. Hyaluronidase temporarily breaks down hyaluronan, a gel-like substance in the subcutaneous tissue, creating space for a larger volume of fluid to disperse and absorb into the systemic circulation without causing severe localized swelling or pain.

Clinically, the subcutaneous version delivers non-inferior pharmacokinetic exposure and efficacy compared to the intravenous infusion. Practically, it transforms the patient experience. A two-minute injection in a standard exam room replaces an hour-long ordeal in an infusion suite.

For Merck, however, the benefits go far beyond patient convenience. Formulating a biologic for subcutaneous delivery requires distinct manufacturing processes, unique stabilizing excipients, and proprietary enzyme combinations. These innovations carry their own intellectual property protections that extend well into the 2030s. If Merck can successfully transition a substantial percentage of existing and newly diagnosed cancer patients onto the subcutaneous version before 2028, those patients will not automatically switch to generic intravenous biosimilars when the original patents expire. You cannot substitute an intravenous infusion for a subcutaneous injection at the pharmacy counter without changing the entire clinical workflow.

Why Hospitals and Insurers Are Caught in the Middle

The early strength of the subcutaneous launch proves that oncologists and patients welcome the convenience. Yet behind the scenes, a quiet tug-of-war is playing out over reimbursement and clinic economics.

In the United States, oncology practices and hospital outpatient departments have historically relied on the "buy-and-bill" model for intravenous drugs. Under this system, a clinic purchases the expensive infusion drug upfront, administers it to the patient, and bills the insurer for both the medication—often with a small percentage markup—and the facility fees associated with running an infusion chair for an hour. Those facility fees are a vital revenue stream that keeps community oncology clinics financially solvent.

Subcutaneous injections disrupt that financial model. When a patient moves from a thirty-minute IV infusion to a two-minute subcutaneous shot, the clinic loses the lucrative infusion chair billing codes. For large academic medical centers facing severe nursing shortages and six-week waitlists for infusion chairs, freeing up that capacity is a massive operational win. They can cycle more patients through their facilities, improving overall throughput. Smaller, independent oncology practices, however, feel the squeeze on their margins.

Merck’s commercial team has had to navigate this friction carefully. Pricing the subcutaneous formulation near parity with the intravenous version removes sticker shock for payers, while targeted contracting helps offset the administrative shift for providers. Still, the long-term battle will be fought with Pharmacy Benefit Managers and commercial health insurers.

Payers are not naive. They understand lifecycle management strategies intimately, having watched AbbVie defend Humira and Roche defend Herceptin and Rituxan using similar tactics. When cheap intravenous biosimilars of Keytruda arrive in 2028, insurers will inevitably try to force step-therapy protocols—requiring new patients to fail on the discounted IV biosimilar before approving coverage for Merck's branded subcutaneous shot. Merck’s current objective is to build such deep clinical preference and habitual adoption over the next two years that insurers face fierce backlash from oncologists and patient advocacy groups if they attempt to restrict access.

Looking Beyond the Headline Earnings Beat

While the subcutaneous rollout grabbed the headlines in the latest quarterly report, the raised profit outlook reflects several moving parts inside Merck’s broader business. A closer look at the numbers reveals both genuine operational strength and areas where growth is starting to plateau.

First, foreign exchange headwinds that battered multinational pharmaceutical companies over the past two years have begun to stabilize, providing a cleaner translation of international sales back into U.S. dollars. Second, Merck has exercised tight discipline over its operating expenses, carefully managing selling, general, and administrative costs even while funding a massive late-stage clinical trial apparatus.

Then there is the rest of the portfolio. To survive the 2028 cliff, Merck cannot rely solely on converting Keytruda patients; it has to build entirely new revenue pillars. The company has spent tens of billions of dollars on business development to acquire external assets, and the early returns are mixed.

Winrevair, acquired through the $11.5 billion buyout of Acceleron Pharma, has emerged as a genuine bright spot. Approved for pulmonary arterial hypertension, the drug represents a first-in-class activin signaling inhibitor that actually reverses vascular remodeling rather than just dilating blood vessels. Its commercial trajectory has consistently beaten consensus estimates, proving that pulmonologists are eager for disease-modifying therapies despite complex monitoring requirements for bleeding and elevated hemoglobin levels.

Conversely, Gardasil, Merck’s human papillomavirus vaccine and its second-largest product, has hit rough waters. After years of explosive growth driven by surging demand in China, shipments to that region have slowed sharply due to broader macroeconomic weakness, shifting consumer spending habits, and local inventory digestion. This slowdown serves as a sobering reminder that even blockbuster franchises are vulnerable to geopolitical and regional economic shifts. Whenever one pillar wobbles, the pressure on Keytruda—and its subcutaneous successor—intensifies.

The Competitive Threat Nobody Can Afford to Ignore

Even if Merck executes its subcutaneous conversion flawlessly, it faces a threat that patent extensions cannot stop: superior science from rival laboratories.

For a decade, Keytruda has been the undisputed king of immuno-oncology. By blocking the PD-1 receptor on T-cells, it strips away the camouflage that cancer cells use to hide from the immune system. It became the foundational backbone upon which almost every other cancer therapy was tested. If you were a biotech company developing a new targeted therapy, you tested it in combination with Keytruda.

That dominance is now facing its most credible clinical challenge. Next-generation bispecific antibodies are entering late-stage development and posting data that has forced the entire oncology sector to recalibrate. Specifically, drugs targeting both PD-1 and VEGF—vascular endothelial growth factor—are demonstrating the ability to simultaneously unleash the immune system and starve tumors of their blood supply within a single molecule.

In a hypothetical clinical scenario where a community oncologist is treating a newly diagnosed patient with advanced non-small cell lung cancer, the choice is no longer just between IV Keytruda and subcutaneous Keytruda. If a competing bispecific antibody demonstrates superior progression-free survival in head-to-head trials, convenience becomes secondary. Oncologists prioritize efficacy above all else.

Merck is acutely aware of this vulnerability. The company moved aggressively to license its own investigational PD-1/VEGF bispecific antibody from LaNova Medicines, essentially hedging its bets against its own crown jewel. At the same time, Merck is pouring capital into antibody-drug conjugates through a massive collaboration with Daiichi Sankyo, betting that targeted chemotherapy payloads combined with immunotherapy will define the next decade of cancer care.

These deals are smart, defensive necessities, but they are expensive. R&D expenses remain elevated as Merck runs dozens of Phase 3 trials simultaneously, compressing near-term operating margins in exchange for survival in the 2030s.

The Brutal Math of Patent Cliffs

Investors celebrating the raised profit guidance should keep the historical math of the pharmaceutical industry firmly in mind. No company in history has ever completely replaced a $30 billion-a-year franchise without experiencing a period of painful revenue contraction.

When Pfizer lost exclusivity on Lipitor, when AbbVie faced biosimilar competition for Humira, and when Bristol Myers Squibb saw Revlimid generics enter the market, the transition periods were messy. Even when companies successfully launch next-generation formulations or pivot to new therapeutic areas, there is almost always an air pocket where legacy revenues fall faster than new product sales can ramp up.

Merck’s management is attempting to engineer a softer landing than its peers achieved. By getting the subcutaneous version of Keytruda to market early, proving its real-world utility, and driving rapid physician adoption while the intravenous version still enjoys monopoly pricing, the company is locking in market share ahead of the storm. Every percentage point of the Keytruda franchise that migrates to the subcutaneous formulation represents hundreds of millions of dollars in durable, high-margin revenue that will be shielded from the initial wave of 2028 biosimilar erosion.

The quarterly beat and guidance hike confirm that the commercial engine is firing on all cylinders right now. Manufacturing supply chains for the new formulation are holding up, physician feedback on the ease of administration is overwhelmingly positive, and patients are embracing the freedom from the infusion chair.

Yet the real test of Merck's strategy will not be measured in this year's earnings per share or next quarter's revenue beat. It will be decided in the purchasing departments of major hospital networks and the formulary committees of national insurers three years from now, when cheap generic infusions collide head-on with Merck's high-priced subcutaneous convenience.

JL

Julian Lopez

Julian Lopez is an award-winning writer whose work has appeared in leading publications. Specializes in data-driven journalism and investigative reporting.